

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Imanguli, Matin

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Assistant Professor of Otolaryngology-Head and Neck Surgery

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Medical University of Azerbaijan, Baku, Azerbaijan	D.D.S	06/1994	Dentistry
Republican Hospital, Baku, Azerbaijan		06/1995	Oral/Maxillofacial Surgery
Louisiana State University Health Sciences Center, New Orleans, LA		06/2003	Oral Medicine
University of Maryland Medical Center, Baltimore, MD		06/2004	Oral/Maxillofacial Surgery
National Institute of Dental and Craniofacial Research, Bethesda, MD		06/2006	Clinical Research
National Cancer Institute, Bethesda, MD		06/2008	Stem Cell Transplantation/ Immunology
The University of Chicago, Chicago, IL	MD	6/2012	Medicine
University of Texas Southwestern Medical Center, Dallas, TX		06/2017	Otolaryngology Surgery
University of Alabama Medical Center, Birmingham, AL		06/2018	Head and Neck Surgical Oncology and Microvascular Reconstruction

A. Personal Statement

I am a fellowship-trained head and neck surgical oncologist. I have long-standing clinical interest and training in management of head and neck cancer, including mucosal malignancies, cutaneous malignancies of the head and neck and salivary tumors. I also have extensive training in endocrine surgery and skull base surgery. As appropriate, I use open and minimally invasive techniques such as endoscopic, transoral laser and transoral robotic surgery. In addition, my background in Dentistry and Oral and Maxillofacial Surgery gives me a unique comfort level in managing a full scope of head and neck pathology. As a clinical fellow, I was involved in design and management of clinical trials as an associate and principal investigator. My primary research interest is in novel immunotherapeutic approaches to head and neck cancer. I am specifically interested in neoadjuvant and adjuvant immunotherapy and deintensification strategies using immunotherapy in lieu of traditional chemotherapy approaches.

B. Positions and Honors

2018-2019 Assistant Professor and Chief, Division of Head and Neck Oncologic Surgery, Department of Otolaryngology-Head and Neck Surgery, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ

2017-2018 Instructor, Department of Otolaryngology-Head and Neck Surgery, University of Alabama Medical Center, Birmingham, AL

1995-1997 Field Physician, MSF-Belgium (Doctors Without Borders), International humanitarian organization
1997-1999 Medical Officer, Offshore Medical Services Ltd, Private occupational health company, UK
2016-2017 Hospitalist (Part-time Contractor), Access Physicians, Dallas, TX

Honors

1992 Academic Excellence Stipend, Medical University of Azerbaijan
1993 1st Place Awards, Students' Scientific Society Competition, Medical University of Azerbaijan
1994 2nd Place Awards, Students' Scientific Society Competition, Medical University of Azerbaijan
2002 Award for Excellence, American Academy of Oral Medicine
2004 Award for Excellence in Patient Care, Maryland State Senate
2008 Fellow Travel Award, American Society of Bone Marrow Transplantation
2011 Selection to teach Clinical Pathophysiology and Therapeutics, (top 20% of the class), Pritzker School of Medicine, The University of Chicago
2011 Calvin Fentress Research Fellowship, Pritzker School of Medicine, The University of Chicago

C. Contributions to Science

1. Characterized tissue resident and circulating immune cells in chronic oral graft versus host disease (GVHD) supporting for the first time the role of type I interferons in this condition.

Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ and Hakim FT. Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa. *Blood* 2009 Apr 9; 113(15):3620-30 (Featured on Cover).

Imanguli M, Cowen EW, Rose J3, Dhamala S, Swaim W, Lafond S, Yagi B, Gress RE, Pavletic SZ, Hakim FT. Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease. *Leukemia*. 2014 Oct; 28(10):2016-27.

Hakim FT, Memon S, Jin P, **Imanguli MM**, Wang H, Rehman N, Yan XY, Rose J, Mays JW, Dhamala S, Kapoor V, Telford W, Dickinson J, Davis S, Halverson D, Naik HB, Baird K, Fowler D, Stroncek D, Cowen EW, Pavletic SZ, Gress RE. Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease. *J Immunol*. 2016 Nov 1; 197(9):3490-3503. Epub 2016 Sep.

2. Described and characterized in detail salivary gland disease involvement in chronic GVHD

Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, Datiles MB, Hakim FT, Kleiner DE, Krumlauf MC and Pavletic SZ. Salivary Gland Involvement in Chronic Graft versus Host Disease: Prevalence, Clinical Significance and Guidelines for Evaluation. *Biology of Blood and Marrow Transplantation* 2010 Oct; 16(10):1362-9.

Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett JA, Bishop MR, Childs RW, Fowler DH, Pavletic SZ and Hart TC. Changes in Salivary Proteome after Allogeneic Hematopoietic Stem Cell Transplantation. *Experimental Hematology* 2007 Feb; 35(2):184-92.

3. Contributed to development and validation of severity and response assessment scale in chronic GVHD (for oral cavity involvement).

Mitchell SA, Jacobsohn DA, Thormann Powers KE, Carpenter PA, Flowers, MED, Cowen EW, Schubert M, Turner M, Lee SJ, Martin P, Bishop MR, Baird K, Bolanos-Meade J, Boyd K, Fall-Dickson JM, Gerber LH, Guadagnini J, **Imanguli MM**, Krumlauf MC, Lawley L, Li L, Reeve BR, Clayton JA, Vogelsang JB, Pavletic SZ. A Multi-Center Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. *Biology of Blood and Marrow Transplantation* 2011 Nov; 17(11):1619-29.

D. Additional Information: Research Support and/or Scholastic Performance

Quality of Life and Circulating Tumor DNA in Oropharyngeal Cancer Treated with Transoral Surgery and Reduced Intensity Adjuvant Therapy.

Principal Investigator, Investigator Initiated Clinical Trial (CINJ #032008)

Indocyanine Green Second Window Imaging in Head and Neck Cancer

Principal Investigator, Investigator Initiated Clinical Trial

Sponsor: Stryker Corporation

Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial

National Institutes of Health RO1CA240344-01. Principal Investigator Sharon Manne, PhD.

Co-Investigator (5% effort)

NRG-HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer (CINJ #032103).

Co-Investigator, Site PI for CINJ New Brunswick

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer (CINJ #032011)

Co-Investigator

Biospecimen Procurement for Cancer Immunotherapy Protocols at Rutgers Cancer Institute. (CINJ #192002)

Co-Investigator